Update: CPIC ivacaftor-CFTR guideline

The CPIC guideline for ivacaftor treatment based on CFTR genotype has been updated on PharmGKB, in light of changes to the FDA-approved drug label.

Originally, ivacaftor was indicated only in patients with the G551D variant. This has now been extended to other variants that result in CFTR gating defects:

> View the updated CPIC ivacaftor-CFTR guideline.

Figure 1: Treatment algorithm for clinical use of ivacaftor for cystic fibrosis patients based on CFTR genotype.

Subscribe to ClinPGx Blog

Don’t miss out on the latest issues. Sign up now to get access to the library of members-only issues.